title: Value of blood tests including serum group IIA phospholipase A2 and bactericidal/permeability-increasing protein in Crohn's disease.
abstract: OBJECTIVE
  Determination of the activity of Crohn's disease at a defined time-point is a challenging task since only endoscopy guidelines are given and secondary clinical findings, subjective symptoms and non-specific laboratory tests have therefore to be relied on. The purpose of the current study was to investigate the ability of blood tests to differentiate patient groups with different clinical disease activity and different clinical outcomes during follow-up in Crohn's disease.
  
  
  METHODS
  During a visit to hospital, 73 outpatients with Crohn's disease were examined, a clinical score was calculated and blood samples were collected for 22 laboratory tests. The patients were also grouped according to clinical outcome during a 6-year follow-up.
  
  
  RESULTS
  Serum group IIA phospholipase A2 and alpha-1-antitrypsin values were outside the reference interval more frequently (62% and 42%, respectively) than the other tests in active Crohn's disease. Only weak correlations were found between the clinical score and the test values, and the best correlation was found with serum lysozyme (r = 0.40). In a logistic regression model, the best prediction of disease activity at entry to the study was reached with a model including serum orosomucoid and serum lysozyme and the best prediction of clinical outcome during follow-up was reached using a model including serum albumin.
  
  
  CONCLUSIONS
  Serum group IIA phospholipase A2 appeared to be the most sensitive marker of inflammation in Crohn's disease among the 22 blood tests compared. No reliable predictions of disease activity at the time of blood sampling or clinical outcome later during follow-up could be made from the blood tests studied.
authors.affiliation: Department of Surgical and Perioperative Sciences, Surgery, Umeå University Hospital, Umeå, Sweden. markku.haapamaki@vll.se
authors.forename: M M
authors.initials: MM
authors.lastname: Haapamäki
authors.forename: J
authors.initials: J
authors.lastname: Grönroos
authors.forename: H
authors.initials: H
authors.lastname: Nurmi
authors.forename: K
authors.initials: K
authors.lastname: Irjala
authors.forename: H
authors.initials: H
authors.lastname: Peuravuori
authors.forename: T J
authors.initials: TJ
authors.lastname: Nevalainen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D023181:Antimicrobial Cationic Peptides / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins; D003424:Crohn Disease / Q000175:diagnosis*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D054501:Group II Phospholipases A2; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D010741:Phospholipases A / Q000097:blood*; D054467:Phospholipases A2; D012044:Regression Analysis
chemical_list: D023181:Antimicrobial Cationic Peptides; D015415:Biomarkers; D001798:Blood Proteins; D008565:Membrane Proteins; C021623:bactericidal permeability increasing protein; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2